CN106536524B - 用于在增殖性疾病的治疗中使用的[1,2,4]三唑并[4,3-b]哒嗪 - Google Patents

用于在增殖性疾病的治疗中使用的[1,2,4]三唑并[4,3-b]哒嗪 Download PDF

Info

Publication number
CN106536524B
CN106536524B CN201580039278.2A CN201580039278A CN106536524B CN 106536524 B CN106536524 B CN 106536524B CN 201580039278 A CN201580039278 A CN 201580039278A CN 106536524 B CN106536524 B CN 106536524B
Authority
CN
China
Prior art keywords
compound
hydroxy
pharmaceutically acceptable
naphthoic acid
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580039278.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN106536524A (zh
Inventor
R·H·布拉德伯里
A·A·拉博
M·J·韦林
J·F·麦凯布
S·C·格洛索普
A·马哈茂德
Z·A·科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN106536524A publication Critical patent/CN106536524A/zh
Application granted granted Critical
Publication of CN106536524B publication Critical patent/CN106536524B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Geology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Environmental & Geological Engineering (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Fluid Mechanics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580039278.2A 2014-07-28 2015-07-24 用于在增殖性疾病的治疗中使用的[1,2,4]三唑并[4,3-b]哒嗪 Expired - Fee Related CN106536524B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
US62/029,676 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
CN106536524A CN106536524A (zh) 2017-03-22
CN106536524B true CN106536524B (zh) 2019-11-15

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580039278.2A Expired - Fee Related CN106536524B (zh) 2014-07-28 2015-07-24 用于在增殖性疾病的治疗中使用的[1,2,4]三唑并[4,3-b]哒嗪

Country Status (37)

Country Link
US (5) US9944650B2 (https=)
EP (1) EP3174881B1 (https=)
JP (1) JP6592503B2 (https=)
KR (1) KR20170033427A (https=)
CN (1) CN106536524B (https=)
AP (1) AP2017009700A0 (https=)
AU (1) AU2015295120B2 (https=)
BR (1) BR112017001160A2 (https=)
CA (2) CA2956421C (https=)
CL (1) CL2017000223A1 (https=)
CO (1) CO2017001918A2 (https=)
CY (1) CY1120602T1 (https=)
DK (1) DK3174881T3 (https=)
DO (1) DOP2017000018A (https=)
EA (1) EA032654B9 (https=)
ES (1) ES2670444T3 (https=)
GT (1) GT201700016A (https=)
HR (1) HRP20180788T1 (https=)
HU (1) HUE037571T2 (https=)
IL (1) IL250104B (https=)
LT (1) LT3174881T (https=)
MX (1) MX374539B (https=)
MY (1) MY187251A (https=)
NI (1) NI201700006A (https=)
NO (2) NO2719005T3 (https=)
PE (1) PE20170527A1 (https=)
PH (1) PH12017500159B1 (https=)
PL (1) PL3174881T3 (https=)
PT (1) PT3174881T (https=)
RS (1) RS57242B1 (https=)
SG (1) SG11201700419SA (https=)
SI (1) SI3174881T1 (https=)
SM (1) SMT201800260T1 (https=)
SV (1) SV2017005368A (https=)
TN (1) TN2017000018A1 (https=)
WO (1) WO2016016618A1 (https=)
ZA (1) ZA201701207B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (https=) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
EP4045049A1 (en) 2019-10-14 2022-08-24 Astrazeneca AB Combination therapy for treating a hematological malignancy
CA3166741A1 (en) 2020-01-09 2021-07-15 Astrazeneca Ab Combination therapy for treating cancer
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101326186A (zh) * 2005-12-08 2008-12-17 诺瓦提斯公司 作为EphB和VEGFR2激酶抑制剂的吡唑并[1,5-a]吡啶-3-甲酸类化合物
CN102388048A (zh) * 2009-02-10 2012-03-21 阿斯利康(瑞典)有限公司 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途
CN102482280A (zh) * 2009-05-11 2012-05-30 阿斯利康(瑞典)有限公司 作为雄激素受体的配体的[1，2，4]三唑并[4，3-b]哒嗪

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006322187A1 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
BRPI0821676A2 (pt) * 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
ES2563057T3 (es) 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
EP2721031B1 (en) * 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (https=) * 2014-07-28 2018-01-20

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101326186A (zh) * 2005-12-08 2008-12-17 诺瓦提斯公司 作为EphB和VEGFR2激酶抑制剂的吡唑并[1,5-a]吡啶-3-甲酸类化合物
CN102388048A (zh) * 2009-02-10 2012-03-21 阿斯利康(瑞典)有限公司 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途
CN102482280A (zh) * 2009-05-11 2012-05-30 阿斯利康(瑞典)有限公司 作为雄激素受体的配体的[1，2，4]三唑并[4，3-b]哒嗪

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors;Pradip Jadav et al.;《Bioorganic & Medicinal Chemistry Letters》;20140312;第24卷;第1918-1922页 *
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer;Robert H.Bradbury et al.;《Bioorganic & Medicinal Chemistry Letters》;20130221;第23卷;第1945-1948页 *

Also Published As

Publication number Publication date
HRP20180788T1 (hr) 2018-06-29
NO2719005T3 (https=) 2018-01-20
EA201790179A1 (ru) 2017-07-31
JP2017522338A (ja) 2017-08-10
RS57242B1 (sr) 2018-07-31
TN2017000018A1 (en) 2018-07-04
DK3174881T3 (en) 2018-06-06
CY1120602T1 (el) 2019-12-11
SMT201800260T1 (it) 2018-07-17
CL2017000223A1 (es) 2017-08-25
US20180230158A1 (en) 2018-08-16
IL250104A0 (en) 2017-03-30
PH12017500159B1 (en) 2020-12-09
CA3185741A1 (en) 2016-02-04
NI201700006A (es) 2017-08-25
BR112017001160A2 (pt) 2017-11-14
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
US10407432B2 (en) 2019-09-10
EA032654B1 (ru) 2019-06-28
AP2017009700A0 (en) 2017-01-31
MX374539B (es) 2025-03-06
ZA201701207B (en) 2018-12-19
EP3174881A1 (en) 2017-06-07
CN106536524A (zh) 2017-03-22
PH12017500159A1 (en) 2017-07-10
MY187251A (en) 2021-09-15
AU2015295120B2 (en) 2018-02-01
EA032654B9 (ru) 2019-07-31
EP3174881B1 (en) 2018-03-28
US20200055861A1 (en) 2020-02-20
WO2016016618A1 (en) 2016-02-04
US20210107905A1 (en) 2021-04-15
ES2670444T3 (es) 2018-05-30
US20170210747A1 (en) 2017-07-27
HUE037571T2 (hu) 2018-09-28
CA2956421A1 (en) 2016-02-04
SI3174881T1 (en) 2018-06-29
LT3174881T (lt) 2018-06-11
KR20170033427A (ko) 2017-03-24
SV2017005368A (es) 2017-05-12
AU2015295120A8 (en) 2017-02-09
SG11201700419SA (en) 2017-02-27
US10766905B2 (en) 2020-09-08
DOP2017000018A (es) 2017-03-15
CO2017001918A2 (es) 2017-05-10
JP6592503B2 (ja) 2019-10-16
US11407755B2 (en) 2022-08-09
GT201700016A (es) 2018-12-19
US9944650B2 (en) 2018-04-17
IL250104B (en) 2018-10-31
CA2956421C (en) 2023-03-14
NO3174881T3 (https=) 2018-08-25
PT3174881T (pt) 2018-05-25
AU2015295120A1 (en) 2017-02-02
US20230035133A1 (en) 2023-02-02
PL3174881T3 (pl) 2018-08-31

Similar Documents

Publication Publication Date Title
EP4157837B1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20230035133A1 (en) [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
CN108137576B (zh) 8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-异丙基-咪唑并[4，5-c]喹啉-2-酮衍生物
WO2018137639A1 (zh) 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
CN108349971A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
JP7436465B2 (ja) 毛細血管拡張性運動失調症変異（ＡＴＭ）キナーゼの選択的調節物質としての１－イソプロピル－３－メチル－８－（ピリジン－３－イル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］シンノリン－２－オンおよびその使用
CN108348515A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN110603256A (zh) 可用作wee-1激酶抑制剂的嘧啶并嘧啶酮
TW201728577A (zh) 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
TW201808948A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它們在治療癌症中之用途
CN102482280A (zh) 作为雄激素受体的配体的[1，2，4]三唑并[4，3-b]哒嗪
JP6586463B2 (ja) ＰＩ３Ｋβ阻害剤としての複素環連結イミダゾピリダジン誘導体
HK1235059B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
HK1235059A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
EA046212B1 (ru) Азепановые ингибиторы взаимодействия менин–mll
JP2010031001A (ja) 複素環化合物、その製造法および用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191115

CF01 Termination of patent right due to non-payment of annual fee